β-thalassemias: paradigmatic diseases for scientific discoveries and development of innovative therapies
about
Genomic approaches to identifying targets for treating β hemoglobinopathiesThe European Hematology Association Roadmap for European Hematology Research: a consensus documentTargeting iron metabolism in drug discovery and deliveryHbE/β-Thalassemia and Oxidative Stress: The Key to Pathophysiological Mechanisms and Novel Therapeutics.Minihepcidin peptides as disease modifiers in mice affected by β-thalassemia and polycythemia veraGuidelines on Beta-thalassemia major - regular blood transfusion therapy: Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular: project guidelines: Associação Médica Brasileira - 2016.β-Thalassemia Patients Revealed a Significant Change of Untargeted Metabolites in Comparison to Healthy Individuals.Comparison of deferasirox and deferoxamine effects on iron overload and immunological changes in patients with blood transfusion-dependent β-thalassemia.A complicated disease: what can be done to manage thalassemia major more effectively?Ineffective erythropoiesis and regulation of iron status in iron loading anaemias.Thalassemia 2016: Modern medicine battles an ancient disease.Neomorphic effects of the neonatal anemia (Nan-Eklf) mutation contribute to deficits throughout development.A Red Carpet for Iron Metabolism.Investigational drugs in phase I and phase II clinical trials for thalassemia.Molecular Characterization of β-Thalassemia in the Czech and Slovak Populations: Mediterranean, Asian and Unique Mutations.Resolutions for the New YearCombination of Tmprss6- ASO and the iron chelator deferiprone improves erythropoiesis and reduces iron overload in a mouse model of beta-thalassemia intermedia.Skin Disorders in Egyptian Children with β-Thalassemia Major.What can we learn from ineffective erythropoiesis in thalassemia?Inhibition of heme oxygenase ameliorates anemia and reduces iron overload in a β-thalassemia mouse model.Risk adjusted therapy in chronic lymphocytic leukemia: a phase II cancer trials Ireland (CTRIAL-IE [ICORG 07-01]) study of fludarabine, cyclophosphamide, and rituximab therapy evaluating response adapted, abbreviated frontline therapy with FCR in noComparison of MicroRNAs Mediated in Reactivation of the γ-Globin in β-Thalassemia Patients, Responders and Non-Responders to Hydroxyurea.Hepcidin agonists as therapeutic tools.Depression, Anxiety, and Perceived Social Support among Adults with Beta-Thalassemia Major: Cross-Sectional Study.
P2860
Q26799214-A62076F1-5B81-4C28-AAD5-ADEBB294A229Q28830861-27482E27-4EE9-4342-B201-379F015911F6Q33757232-EE71A175-942F-4BE0-8FDA-3513B15FB4F2Q36138738-E0EC9C00-BB84-4056-AEED-8A2CAEF8B602Q37097115-6AD6B999-B9D0-4352-93CF-35415D46439DQ37429238-695D7D9B-5B5D-444E-9130-A1AB2A7F9D6CQ37638068-C5F53252-2733-45BF-B311-CA128F11E421Q37692645-7EDD8703-66D0-445B-BC2B-55CB0A1FD455Q38607875-216A94B8-D844-4360-AAE6-070E8B1F5F40Q38613789-F18C351F-6089-4FD7-86E4-F56F971BE472Q38625435-D73997D5-3A95-44AA-BBFD-13F1E2023373Q38988198-06CA0F3F-C4B9-410D-95A3-A0A2AB40C7F0Q39106718-BD0D045A-C244-454D-B851-90EC91C81BB5Q39328286-6D9533B2-FDCA-4E31-A5FD-88BE9A5D4CE3Q40865017-49F0D77A-EFD0-4895-B3F6-DF5335A75361Q42722329-6E2E359A-C340-4C5B-8F4F-63ADC04F0E2AQ43109013-BFE02521-D515-4B91-8D24-F547903E55EEQ47371612-DE1DB35C-E562-4E40-8FF0-3284969DBB49Q47885433-BF9051E5-920B-43B5-B6D8-07D196067F64Q48228826-DBFF11C0-C6DC-4685-AFA3-FBB404F5661AQ50025029-EACB692B-EEA6-4BBA-9607-EA822F8E3EE8Q50897207-A73F0FFF-01EE-4942-A2B5-F1F090453DE1Q52663760-45CA692B-7239-49D2-85BE-E7B51A5710A9Q55082196-DB467422-DCB3-4A8E-9DCF-9751844B9F58
P2860
β-thalassemias: paradigmatic diseases for scientific discoveries and development of innovative therapies
description
2015 nî lūn-bûn
@nan
2015 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
β-thalassemias: paradigmatic d ...... opment of innovative therapies
@ast
β-thalassemias: paradigmatic d ...... opment of innovative therapies
@en
β-thalassemias: paradigmatic d ...... opment of innovative therapies
@nl
type
label
β-thalassemias: paradigmatic d ...... opment of innovative therapies
@ast
β-thalassemias: paradigmatic d ...... opment of innovative therapies
@en
β-thalassemias: paradigmatic d ...... opment of innovative therapies
@nl
prefLabel
β-thalassemias: paradigmatic d ...... opment of innovative therapies
@ast
β-thalassemias: paradigmatic d ...... opment of innovative therapies
@en
β-thalassemias: paradigmatic d ...... opment of innovative therapies
@nl
P2860
P3181
P1433
P1476
β-thalassemias: paradigmatic d ...... opment of innovative therapies
@en
P2093
S. Rivella
P2860
P304
P3181
P356
10.3324/HAEMATOL.2014.114827
P407
P577
2015-04-01T00:00:00Z